降纤酶、低分子肝素联合应用治疗急性脑梗死的临床观察

目的 观察降纤酶、低分子肝素联合应用治疗急性脑梗死是否优于巴曲抗栓酶及其安全性。方法 93例急性脑梗死病人随机分成2组,治疗组(52例)用低分子肝素2500U,每12h皮下注射1次;降纤酶10U、5U、5U各加入0.9％氯化钠注射液250ml分别于入院第1、3、5天静脉点滴,滴注时间为l～1.5h。对照组(41例)应用巴曲抗栓酶,用法同治疗组降纤酶。分别观察2组治疗前后血液学改变及临床疗效。结果 治疗组凝血酶原时间、纤维蛋白原量均较治疗前有明显改善,组间比较差异显著(P<0.01、0.05)。治疗组总有效率及显效率分别为92.3％、69.2％;对照组总有效率及显效率分别为83.0％、48.8％,2组比较差异非常显著(P<0.01)。治疗组及对照组均未发现出血性脑梗死情况。结论 降纤酶、低分子肝素联合应用治疗急性脑梗死,其改善血液学及临床疗效方面均优于巴曲抗栓酶,且安全、实用。

Treatment of acute cerebral infarction with defibrase and low-molecular-weight haparin calcium

Objective To search for effective and safety treating acute cerebral infarction with defibrase and low-molecular-weight haparin calcium. Methods 93 patients with acute cerebral infarction were randomly divided into two groups.Treatment group was treated with defibrase,of which 10 U,5 U,5 U was dissolved in 0.9% Nacl solution 250 ml and intravenous drip for 1 - 1.5 hour at the first, third, fifth day respectively. Simultaneously, 2 500 U of low-molecular-weight haparin calcium was given through hypodermic injection at a time per 12 hours. Control group was treated with batroxobin by same therapy as defibrase. Hematological changes and clinical effect were observed before and after treatment. Results The total effective rate of the treatment group was better than that of the control group ( P < 0.01); hemotological changes including fibrinogen dose and thrombinogen time were improved after treatment, but treatment group was better than control group( P < 0.05、0.01).The hemorrhagic cerebral infarction is not found in both group. Conclusion It is effective and safety therapy that the acute cerebral infarction is treated by Defibrase combined with low-molecular-weight haparin calcium.